Skip to main content

Advertisement

SpringerLink
Log in

Postmastectomy radiotherapy in intermediate-risk patients: The gray zone

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Postmastectomy radiotherapy continues to be one of the most controversial issues in breast radiotherapy. At the crux of the controversy lies the lack of conclusive studies that specifically address the risk-benefit ratio of postmastectomy radiotherapy for patients at intermediate risk of developing locoregional recurrence. A well-designed phase III trial was initiated, but the trial failed to accrue and was closed prematurely, leaving the issue unresolved. Recent data confirm that postmastectomy radiotherapy yields a clear benefit in breast cancer-specific survival. Furthermore, the risk of cardiac morbidity that historically has offset the benefit of postmastectomy radiotherapy appears to be lessening with modern radiotherapy approaches. However, newer, more efficacious systemic therapy regimens may decrease the risk of locoregional recurrence and increase the risk of toxicity from combined-modality therapy. Recent studies attempt to better stratify patients into risk categories based on disease factors and to estimate the benefit of postmastectomy radiotherapy when traditional risk estimates, such as nodal status, are obscured by neoadjuvant systemic therapy. Nonetheless, a clear consensus on the role of postmastectomy radiotherapy remains elusive for patients who are at intermediate risk of locoregional recurrence after mastectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pierce LJ, Lichter AS: Defining the role of post-mastectomy radiotherapy: the new evidence. Oncology (Huntingt) 1996, 10:991–1002, discussion 1006–1007, 1011.

    CAS  Google Scholar 

  2. Sartor CI: Postmastectomy radiotherapy in women with breast cancer metastatic to one to three axillary lymph nodes. Curr Oncol Rep 2001, 3:497–505.

    PubMed  CAS  Google Scholar 

  3. Recht A, Bartelink H, Fourquet A, et al.: Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 1998, 16:2886–2889.

    PubMed  CAS  Google Scholar 

  4. Marks LB, Prosnitz LR: "One to three" or "four or more"?: selecting patients for postmastectomy radiation therapy. Cancer 1997, 79:668–670.

    Article  PubMed  CAS  Google Scholar 

  5. Pierce LJ: The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 2005, 23:1706–1717.

    Article  PubMed  Google Scholar 

  6. Ragaz J, Jackson SM, Le N, et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956–962.

    Article  PubMed  CAS  Google Scholar 

  7. Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337:949–955. This practice-changing randomized trial demonstrated a survival benefit of PMRT in node-positive patients treated with systemic therapy.

    Article  PubMed  CAS  Google Scholar 

  8. Overgaard M, Jensen MB, Overgaard J, et al.: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999, 353:1641–1648. This practice-changing randomized trial demonstrated a survival benefit of PMRT in node-positive patients treated with systemic therapy.

    Article  PubMed  CAS  Google Scholar 

  9. Ragaz J, Olivotto IA, Spinelli JJ, et al.: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97:116–126. This practice-changing randomized trial demonstrated a survival bene fit of PMRT in node-positive patients treated with systemic therapy.

    Article  PubMed  Google Scholar 

  10. Recht A, Edge SB, Solin LJ, et al.: Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1539–1569.

    PubMed  CAS  Google Scholar 

  11. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 2001:5-15.

  12. Harris JR, Halpin-Murphy P, McNeese M, et al.: Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999, 44:989–990.

    Article  PubMed  CAS  Google Scholar 

  13. Early Breast Cancer Trialists’ Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 1995, 333:1444–1455.

    Article  Google Scholar 

  14. Early Breast Cancer Trialists’ Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000, 355:1757–1770. This meta-analysis of adjuvant radiotherapy demonstrates a breast cancer-specific survival advantage offset by increase in cardiovascular mortality.

    Article  Google Scholar 

  15. Recht A, Gray R, Davidson NE, et al.: Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999, 17:1689–1700. This compilation of locoregional recurrence data from several randomized trials provides a benchmark for risk estimates.

    PubMed  CAS  Google Scholar 

  16. Wallgren A, Bonetti M, Gelber RD, et al.: Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 2003, 21:1205–1213. This compilation of locoregional recurrence data from several randomized trials provides a benchmark for risk estimates.

    Article  PubMed  CAS  Google Scholar 

  17. Taghian A, Jeong JH, Mamounas E, et al.: Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 2004, 22:4247–4254. This compilation of locoregional recurrence data from several randomized trials provides a benchmark for risk estimates.

    Article  PubMed  Google Scholar 

  18. Truong PT, Olivotto IA, Kader HA, et al.: Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2005, 61:1337–1347. This retrospective study identifies features that can stratify patients with one to three involved lymph nodes into higher risk categories.

    Article  PubMed  Google Scholar 

  19. Truong PT, Lesperance M, Culhaci A, et al.: Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 2005, 62:175–182. This retrospective study identifies features that can stratify nodenegative patients into higher risk categories.

    Article  PubMed  Google Scholar 

  20. Jagsi R, Raad RA, Goldberg S, et al.: Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005, 62:1035–1039. This retrospective study identifies features that can stratify nodenegative patients into higher risk categories.

    Article  PubMed  Google Scholar 

  21. Sartor CI, Peterson BL, Woolf S, et al.: Effect of addition of adjuvant Paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 2005, 23:30–40.

    Article  PubMed  CAS  Google Scholar 

  22. Fisher ER, Wang J, Bryant J, et al.: Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002, 95:681–695.

    Article  PubMed  Google Scholar 

  23. Garg AK, Strom EA, McNeese MD, et al.: T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:138–145.

    Article  PubMed  Google Scholar 

  24. Huang EH, Tucker SL, Strom EA, et al.: Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004, 22:4691–4699.

    Article  PubMed  Google Scholar 

  25. Cuzick J, Stewart H, Rutqvist L, et al.: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994, 12:447–453.26.

    PubMed  CAS  Google Scholar 

  26. Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005, 6:557–565.

    Article  PubMed  Google Scholar 

  27. Giordano SH, Kuo YF, Freeman JL, et al.: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97:419–424.

    Article  PubMed  Google Scholar 

  28. Hojris I, Overgaard M, Christensen JJ, et al.: Morbidity and mortality of ischaemic heart disease in high-risk breastcancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999, 354:1425–1430.

    Article  PubMed  CAS  Google Scholar 

  29. Ceilley E, Jagsi R, Goldberg S, et al.: Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 2005, 61:365–373.

    Article  PubMed  Google Scholar 

  30. White J, Moughan J, Pierce LJ, et al.: Status of postmastectomy radiotherapy in the United States: a patterns of care study. Int J Radiat Oncol Biol Phys 2004, 60:77–85.

    Article  PubMed  Google Scholar 

  31. Taghian A, Jagsi R, Makris A, et al.: Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol Phys 2004, 60:706–714.

    Article  PubMed  Google Scholar 

  32. Stemmer SM, Rizel S, Hardan I, et al.: The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol 2003, 21:2713–2718.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of North Carolina School of Medicine, 101 Manning Drive, 27599, Chapel Hill, NC, USA

    Carolyn I. Sartor MD

Authors
  1. Carolyn I. Sartor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carolyn I. Sartor MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sartor, C.I. Postmastectomy radiotherapy in intermediate-risk patients: The gray zone. Curr Oncol Rep 8, 29–34 (2006). https://doi.org/10.1007/s11912-006-0006-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0006-8

Keywords

Search

Navigation